Postdependent state in rats as a model for medication development in alcoholism

Addiction Biology

Volumn 20, Issue 1, 2015, Pages 1-21

  Meinhardt, Marcus W ^a   Sommer, Wolfgang H ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Alcoholism; animal models; postdependent state

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ALCOHOL; ALLOSTERIC MODULATOR; DOPAMINE RECEPTOR BLOCKING AGENT; DRUGS USED IN THE TREATMENT OF ADDICTION; GLUTAMATE RECEPTOR AGONIST; GLUTAMATE RECEPTOR ANTAGONIST; OPIATE ANTAGONIST; UNCLASSIFIED DRUG; CENTRAL DEPRESSANT AGENT;

ALCOHOL CONSUMPTION; ALCOHOL INTOXICATION; ALCOHOL USE DISORDER; ALCOHOLISM; ANIMAL BEHAVIOR; ANIMAL MODEL; BRAIN FUNCTION; BRAIN STRESS SYSTEM; DRINKING BEHAVIOR; DRUG DEPENDENCE TREATMENT; DRUG DEVELOPMENT; DRUG TARGETING; DSM-5; DSM-IV; EVIDENCE BASED PRACTICE; LONG TERM EXPOSURE; MOTIVATION; NEUROMODULATION; NONHUMAN; RAT; RAT MODEL; REVIEW; STRESS; AFFECT; ANIMAL; DISEASE MODEL; PHENOTYPE; SUBSTANCE WITHDRAWAL SYNDROME;

AFFECT; ALCOHOLISM; ANIMALS; CENTRAL NERVOUS SYSTEM DEPRESSANTS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; ETHANOL; PHENOTYPE; RATS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84919846348     PISSN: 13556215     EISSN: 13691600     Source Type: Journal    
DOI: 10.1111/adb.12187     Document Type: Review

References (168)

1. Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, Abenavoli L, D'Angelo C, Caputo F, Zambon A, Haber PS, Gasbarrini G, (2007) Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 370: 1915-1922.
2. Addolorato G, Leggio L, Ferrulli A, Cardone S, Bedogni G, Caputo F, Gasbarrini G, Landolfi R, (2011) Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol Alcohol 46: 312-317.
3. Ahmed SH, Koob GF, (1998) Transition from moderate to excessive drug intake: change in hedonic set point. Science 282: 298-300.
4. Arlinde C, Sommer W, Björk K, Reimers M, Hyytiä P, Kiianmaa K, Heilig M, (2004) A cluster of differentially expressed signal transduction genes identified by microarray analysis in a rat genetic model of alcoholism. Pharmacogenomics J 4: 208-218.
5. Aujla H, Cannarsa R, Romualdi P, Ciccocioppo R, Martin-Fardon R, Weiss F, (2013) Modification of anxiety-like behaviors by nociceptin/orphanin FQ (N/OFQ) and time-dependent changes in N/OFQ-NOP gene expression following ethanol withdrawal. Addict Biol 18: 467-479.
6. Ayanwuyi LO, Carvajal F, Lerma-Cabrera JM, Domi E, Björk K, Ubaldi M, Heilig M, Roberto M, Ciccocioppo R, Cippitelli A, (2013) Role of a genetic polymorphism in the corticotropin-releasing factor receptor 1 gene in alcohol drinking and seeking behaviors of marchigian sardinian alcohol-preferring rats. Front Psychiatry 4: 23.
7. Bachteler D, Economidou D, Danysz W, Ciccocioppo R, Spanagel R, (2005) The effects of acamprosate and neramexane on cue-induced reinstatement of ethanol-seeking behavior in rat. Neuropsychopharmacology 30: 1104-1110.
8. Bagrov AY, Bagrov YY, Fedorova OV, Kashkin VA, Patkina NA, Zvartau EE, (2002) Endogenous digitalis-like ligands of the sodium pump: possible involvement in mood control and ethanol addiction. Eur Neuropsychopharmacol 12: 1-12.
9. Baptista MAS, Martin-Fardon R, Weiss F, (2004) Preferential effects of the metabotropic glutamate 2/3 receptor agonist LY379268 on conditioned reinstatement versus primary reinforcement: comparison between cocaine and a potent conventional reinforcer. J Neurosci 24: 4723-4727.
10. Basavarajappa BS, (2007) The endocannabinoid signaling system: a potential target for next-generation therapeutics for alcoholism. Mini Rev Med Chem 7: 769-779.
11. Bäckström P, Hyytiä P, (2005) Suppression of alcohol self-administration and cue-induced reinstatement of alcohol seeking by the mGlu2/3 receptor agonist LY379268 and the mGlu8 receptor agonist (S)-3,4-DCPG. Eur J Pharmacol 528: 110-118.
12. Bäckström P, Hyytiä P, (2006) Ionotropic and metabotropic glutamate receptor antagonism attenuates cue-induced cocaine seeking. Neuropsychopharmacology 31: 778-786.
13. Becker HC, (2000) Animal models of alcohol withdrawal. Alcohol Res Health 24: 105-113.
14. Becker HC, Lopez MF, (2004) Increased ethanol drinking after repeated chronic ethanol exposure and withdrawal experience in C57BL/6 mice. Alcohol Clin Exp Res 28: 1829-1838.
15. Belin D, Berson N, Balado E, Piazza PV, Deroche-Gamonet V, (2011) High-novelty-preference rats are predisposed to compulsive cocaine self-administration. Neuropsychopharmacology 36: 569-579.
16. Bell GH, Griffin WC, Patrick KS, (2011) Oral and transdermal DL-methylphenidate-ethanol interactions in C57BL/6J mice: potentiation of locomotor activity with oral delivery. Pharmacol Biochem Behav 100: 264-270.
17. Bell RL, Rodd ZA, Engleman EA, Toalston JE, McBride WJ, (2013) Scheduled access alcohol drinking by alcohol-preferring (P) and high-alcohol-drinking (HAD) rats: modeling adolescent and adult binge-like drinking. Alcohol 48: 225-234.
18. Besheer J, Grondin J, Cannady R, Sharko A, (2010) Glutamate receptor 5 activity in the nucleus accumbens is required for the maintenance of ethanol self-administration in a rat genetic model of high alcohol intake. Biol Psychiatry 67: 812-822.
19. Björk K, Saarikoski ST, Arlinde C, Kovanen L, Osei-Hyiaman D, Ubaldi M, Reimers M, Hyytiä P, Heilig M, Sommer WH, (2006) Glutathione-S-transferase expression in the brain: possible role in ethanol preference and longevity. FASEB J 20: 1826-1835.
20. Björk K, Rimondini R, Hansson AC, Terasmaa A, Hyytiä P, Heilig M, Sommer WH, (2008) Modulation of voluntary ethanol consumption by beta-arrestin 2. FASEB J 22: 2552-2560.
21. Björk K, Hansson AC, Sommer WH, (2010) Genetic variation and brain gene expression in rodent models of alcoholism implications for medication development. Int Rev Neurobiol 91: 129-171.
22. Bossert JM, Gray SM, Lu L, Shaham Y, (2006) Activation of group II metabotropic glutamate receptors in the nucleus accumbens shell attenuates context-induced relapse to heroin seeking. Neuropsychopharmacology 31: 2197-2209.
23. Cannella N, Halbout B, Uhrig S, Evrard L, Corsi M, Corti C, Deroche-Gamonet V, Hansson AC, Spanagel R, (2013) The mGluR2/3 agonist LY379268 induced anti-reinstatement effects in rats exhibiting addiction-like behavior. Neuropsychopharmacology 38: 2048-2056.
24. Chen ACH, Manz N, Tang Y, Rangaswamy M, Almasy L, Kuperman S, Nurnberger J, O'Connor SJ, Edenberg HJ, Schuckit MA, Tischfield J, Foroud T, Bierut LJ, Rohrbaugh J, Rice JP, Goate A, Hesselbrock V, Porjesz B, (2010) Single-nucleotide polymorphisms in corticotropin releasing hormone receptor 1 gene (CRHR1) are associated with quantitative trait of event-related potential and alcohol dependence. Alcohol Clin Exp Res 34: 988-996.
25. Chin C-L, Upadhyay J, Marek GJ, Baker SJ, Zhang M, Mezler M, Fox GB, Day M, (2011) Awake rat pharmacological magnetic resonance imaging as a translational pharmacodynamic biomarker: metabotropic glutamate 2/3 agonist modulation of ketamine-induced blood oxygenation level dependence signals. J Pharmacol Exp Ther 336: 709-715.
26. Ciccocioppo R, Lin D, Martin-Fardon R, Weiss F, (2003) Reinstatement of ethanol-seeking behavior by drug cues following single versus multiple ethanol intoxication in the rat: effects of naltrexone. Psychopharmacology (Berl) 168: 208-215.
27. Ciccocioppo R, Economidou D, Rimondini R, Sommer W, Massi M, Heilig M, (2007) Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system. Biol Psychiatry 61: 4-12.
28. Cippitelli A, Bilbao A, Hansson AC, del Arco I, Sommer W, Heilig M, Massi M, Bermúdez-Silva FJ, Navarro M, Ciccocioppo R, de Fonseca FR, (2005) Cannabinoid CB1 receptor antagonism reduces conditioned reinstatement of ethanol-seeking behavior in rats. Eur J Neurosci 21: 2243-2251.
29. Cippitelli A, Damadzic R, Frankola K, Goldstein A, Thorsell A, Singley E, Eskay RL, Heilig M, (2010) Alcohol-induced neurodegeneration, suppression of transforming growth factor-beta, and cognitive impairment in rats: prevention by group II metabotropic glutamate receptor activation. Biol Psychiatry 67: 823-830.
30. Cippitelli A, Rezvani AH, Robinson JE, Eisenberg L, Levin ED, Bonaventure P, Motley ST, Lovenberg TW, Heilig M, Thorsell A, (2011) The novel, selective, brain-penetrant neuropeptide Y Y2 receptor antagonist, JNJ-31020028, tested in animal models of alcohol consumption, relapse, and anxiety. Alcohol 45: 567-576.
31. Colombo G, Addolorato G, Agabio R, Carai MAM, Pibiri F, Serra S, Vacca G, Gessa GL, (2004) Role of GABA(B) receptor in alcohol dependence: reducing effect of baclofen on alcohol intake and alcohol motivational properties in rats and amelioration of alcohol withdrawal syndrome and alcohol craving in human alcoholics. Neurotox Res 6: 403-414.
32. Crabbe JC, Phillips TJ, Harris RA, Arends MA, Koob GF, (2006) Alcohol-related genes: contributions from studies with genetically engineered mice. Addict Biol 11: 195-269.
33. Daoust M, Saligaut C, Chadelaud M, Chretien P, Moore N, Boismare F, (1984) Attenuation by antidepressant drugs of alcohol intake in rats. Alcohol 1: 379-383.
34. Economidou D, Hansson AC, Weiss F, Terasmaa A, Sommer WH, Cippitelli A, Fedeli A, Martin-Fardon R, Massi M, Ciccocioppo R, Heilig M, (2008) Dysregulation of nociceptin/orphanin FQ activity in the amygdala is linked to excessive alcohol drinking in the rat. Biol Psychiatry 64: 211-218.
35. Edwards S, Guerrero M, Ghoneim OM, Roberts E, Koob GF, (2012) Evidence that vasopressin V1b receptors mediate the transition to excessive drinking in ethanol-dependent rats. Addict Biol 17: 76-85.
36. Egli M, (2005) Can experimental paradigms and animal models be used to discover clinically effective medications for alcoholism? Addict Biol 10: 309-319.
37. Everitt BJ, Robbins TW, (2005) Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci 8: 1481-1489.
38. Files FJ, Samson HH, Denning CE, (2000) Effects of prior ethanol exposure on ethanol self-administration in a continuous access situation using retractable drinking tubes. Alcohol 21: 97-102.
39. Funk CK, O'Dell LE, Crawford EF, Koob GF, (2006) Corticotropin-releasing factor within the central nucleus of the amygdala mediates enhanced ethanol self-administration in withdrawn, ethanol-dependent rats. J Neurosci 26: 11324-11332.
40. Funk CK, Zorrilla EP, Lee M-J, Rice KC, Koob GF, (2007) Corticotropin-releasing factor 1 antagonists selectively reduce ethanol self-administration in ethanol-dependent rats. Biol Psychiatry 61: 78-86.
41. Gadd CA, Murtra P, De Felipe C, Hunt SP, (2003) Neurokinin-1 receptor-expressing neurons in the amygdala modulate morphine reward and anxiety behaviors in the mouse. J Neurosci 23: 8271-8280.
42. Garbutt JC, Kampov-Polevoy AB, Gallop R, Kalka-Juhl L, Flannery BA, (2010) Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res 34: 1849-1857.
43. Gass JT, Olive MF, (2008) Glutamatergic substrates of drug addiction and alcoholism. Biochem Pharmacol 75: 218-265.
44. Gehlert DR, Cippitelli A, Thorsell A, Lê AD, Hipskind PA, Hamdouchi C, Lu J, Hembre EJ, Cramer J, Song M, McKinzie D, Morin M, Ciccocioppo R, Heilig M, (2007) 3-(4-Chloro-2-morpholin-4-yl-thiazol-5-yl)-8-(1-ethylpropyl)-2,6-dimethyl-imidazo[1,2-b]pyridazine: a novel brain-penetrant, orally available corticotropin-releasing factor receptor 1 antagonist with efficacy in animal models of alcoholism. J Neurosci 27: 2718-2726.
45. George DT, Gilman J, Hersh J, Thorsell A, Herion D, Geyer C, Peng X, Kielbasa W, Rawlings R, Brandt JE, Gehlert DR, Tauscher JT, Hunt SP, Hommer D, Heilig M, (2008) Neurokinin 1 receptor antagonism as a possible therapy for alcoholism. Science 319: 1536-1539.
46. George DT, Herion DW, Jones CL, Phillips MJ, Hersh J, Hill D, Heilig M, Ramchandani VA, Geyer C, Spero DE, Singley ED, O'Malley SS, Bishai R, Rawlings RR, Kunos G, (2010) Rimonabant (SR141716) has no effect on alcohol self-administration or endocrine measures in nontreatment-seeking heavy alcohol drinkers. Psychopharmacology (Berl) 208: 37-44.
47. Gilman JM, Hommer DW, (2008) Modulation of brain response to emotional images by alcohol cues in alcohol-dependent patients. Addict Biol 13: 423-434.
48. Gilpin NW, Koob GF, (2010) Effects of β-adrenoceptor antagonists on alcohol drinking by alcohol-dependent rats. Psychopharmacology (Berl) 212: 431-439.
49. Gilpin NW, Richardson HN, Cole M, Koob GF, (2008 a) Vapor inhalation of alcohol in rats. Curr Protoc Neurosci 44: 9.29.1-9.29.19.
50. Gilpin NW, Richardson HN, Koob GF, (2008b) Effects of CRF1-receptor and opioid-receptor antagonists on dependence-induced increases in alcohol drinking by alcohol-preferring (P) rats. Alcohol Clin Exp Res 32: 1535-1542.
51. Gilpin NW, Smith AD, Cole M, Weiss F, Koob GF, Richardson HN, (2009) Operant behavior and alcohol levels in blood and brain of alcohol-dependent rats. Alcohol Clin Exp Res 33: 2113-2123.
52. Goldstein DB, Pal N, (1971) Alcohol dependence produced in mice by inhalation of ethanol: grading the withdrawal reaction. Science 172: 288-290.
53. Gual A, He Y, Torup L, van den Brink W, Mann K, (2013) A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol 23: 1432-1442.
54. Hansson AC, Soverchia L, Terasmaa A, Massi M, Heilig M, Ciccocioppo R, (2006) Variation at the rat Crhr1 locus and sensitivity to relapse into alcohol seeking induced. Proc Natl Acad Sci U S A 103: 15236-15241.
55. Hansson AC, Bermúdez-Silva FJ, Malinen H, Hyytiä P, Sanchez-Vera I, Rimondini R, Rodriguez de Fonseca F, Kunos G, Sommer WH, Heilig M, (2007) Genetic impairment of frontocortical endocannabinoid degradation and high alcohol preference. Neuropsychopharmacology 32: 117-126.
56. Harper C, Corbett D, (1990) Changes in the basal dendrites of cortical pyramidal cells from alcoholic patients-a quantitative Golgi study. J Neurol Neurosurg Psychiatry 53: 856-861.
57. Heilig M, Koob G, (2007) A key role for corticotropin-releasing factor in alcohol dependence. Trends Neurosci 30: 399-406.
58. Heilig M, Koob GF, Ekman R, Britton KT, (1994) Corticotropin-releasing factor and neuropeptide Y: role in emotional integration. Trends Neurosci 17: 80-85.
59. Heilig M, Egli M, Crabbe JC, Becker HC, (2010) Acute withdrawal, protracted abstinence and negative affect in alcoholism: are they linked? Addict Biol 15: 169-184.
60. Heilig M, Goldman D, Berrettini W, O'Brien CP, (2011) Pharmacogenetic approaches to the treatment of alcohol addiction. Nat Rev Neurosci 12: 670-684.
61. Heinrichs SC, Koob GF, (2004) Corticotropin-releasing factor in brain: a role in activation, arousal, and affect regulation. J Pharmacol Exp Ther 311: 427-440.
62. Hermann D, Weber-Fahr W, Sartorius A, Hoerst M, Frischknecht U, Tunc-Skarka N, Perreau-Lenz S, Hansson AC, Krumm B, Kiefer F, Spanagel R, Mann K, Ende G, Sommer WH, (2012) Translational magnetic resonance spectroscopy reveals excessive central glutamate levels during alcohol withdrawal in humans and rats. Biol Psychiatry 71: 1015-1021.
63. Heyser CJ, Schulteis G, Durbin P, (1998) Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats. Neuropsychopharmacology 18: 125-133.
64. Holmes A, Heilig M, Rupniak NMJ, Steckler T, Griebel G, (2003) Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol Sci 24: 580-588.
65. Holmes A, Fitzgerald PJ, MacPherson KP, DeBrouse L, Colacicco G, Flynn SM, Masneuf S, Pleil KE, Li C, Marcinkiewcz CA, Kash TL, Gunduz-Cinar O, Camp M, (2012) Chronic alcohol remodels prefrontal neurons and disrupts NMDAR-mediated fear extinction encoding. Nat Neurosci 15: 1359-1361.
66. Holmes A, Spanagel R, Krystal JH, (2013) Glutamatergic targets for new alcohol medications. Psychopharmacology (Berl) 229: 539-554.
67. Houchi H, Persyn W, Legastelois R, Naassila M, (2013) The adenosine A2A receptor agonist CGS 21680 decreases ethanol self-administration in both non-dependent and dependent animals. Addict Biol 18: 812-825.
68. Hölter SM, Engelmann M, Kirschke C, Liebsch G, Landgraf R, Spanagel R, (1998) Long-term ethanol self-administration with repeated ethanol deprivation episodes changes ethanol drinking pattern and increases anxiety-related behaviour during ethanol deprivation in rats. Behav Pharmacol 9: 41-48.
69. Hyman SE, (2012) Revolution stalled. Sci Transl Med 4: 155cm11.
70. Johnson BA, (2008) Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochem Pharmacol 75: 34-56.
71. Johnson BA, Jasinski DR, Galloway GP, Kranzler H, Weinreib R, Anton RF, Mason BJ, Bohn MJ, Pettinati HM, Rawson R, Clyde C, (1996) Ritanserin in the treatment of alcohol dependence-a multi-center clinical trial. Ritanserin Study Group. Psychopharmacology (Berl) 128: 206-215.
72. Jorde A, Bach P, Witt SH, Becker K, Reinhard I, Vollstädt-Klein S, Kirsch M, Hermann D, Charlet K, Beck A, Wimmer L, Frank J, Treutlein J, Spanagel R, Mann K, Walter H, Heinz A, Rietschel M, Kiefer F, (2014) Genetic variation in the atrial natriuretic peptide transcription factor GATA4 modulates amygdala responsiveness in alcohol dependence. Biol Psychiatry 75: 790-797.
73. Kallupi M, Vendruscolo LF, Carmichael CY, George O, Koob GF, Gilpin NW, (2013) Neuropeptide Y Y 2 R blockade in the central amygdala reduces anxiety-like behavior but not alcohol drinking in alcohol-dependent rats. Addict Biol 19: 755-757.
74. Kanis JA, Johansson H, Johnell O, Oden A, De Laet C, Eisman JA, Pols H, Tenenhouse A, (2005) Alcohol intake as a risk factor for fracture. Osteoporos Int 16: 737-742.
75. Kasanetz F, Deroche-Gamonet V, Berson N, Balado E, Lafourcade M, Manzoni O, Piazza PV, (2010) Transition to addiction is associated with a persistent impairment in synaptic plasticity. Science 328: 1709-1712.
76. Kiefer F, Witt SH, Frank J, Richter A, Treutlein J, Lemenager T, Nöthen MM, Cichon S, Batra A, Berner M, Wodarz N, Zimmermann US, Spanagel R, Wiedemann K, Smolka MN, Heinz A, Rietschel M, Mann K, (2011) Involvement of the atrial natriuretic peptide transcription factor GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate. Pharmacogenomics J 11: 368-374.
77. Kissler JL, Sirohi S, Reis DJ, Jansen HT, Quock RM, Smith DG, Walker BM, (2013) The one-two punch of alcoholism: role of central amygdala dynorphins/kappa-opioid receptors. Biol Psychiatry 75: 774-782.
78. Koob GF, (1999) Corticotropin-releasing factor, norepinephrine, and stress. Biol Psychiatry 46: 1167-1180.
79. Koob GF, (2008) A role for brain stress systems in addiction. Neuron 59: 11-34.
80. Koob GF, Le Moal M, (1997) Drug abuse: hedonic homeostatic dysregulation. Science 278: 52-58.
81. Koob GF, Le Moal M, (2001) Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 24: 97-129.
82. Koob GF, Le Moal M, (2008) Addiction and the brain antireward system. Annu Rev Psychol 59: 29-53.
83. Kroener S, Mulholland PJ, New NN, Gass JT, Becker HC, Chandler LJ, (2012) Chronic alcohol exposure alters behavioral and synaptic plasticity of the rodent prefrontal cortex. PLoS ONE 7: e37541.
84. Kufahl PR, Martin-Fardon R, Weiss F, (2011) Enhanced sensitivity to attenuation of conditioned reinstatement by the mGluR(2/3) agonist LY379268 and increased functional activity of mGluR(2/3) in rats with a history of ethanol dependence. Neuropsychopharmacology 36: 2762-2773.
85. Lê AD, Poulos CX, Harding S, Watchus J, Juzytsch W, Shaham Y, (1999) Effects of naltrexone and fluoxetine on alcohol self-administration and reinstatement of alcohol seeking induced by priming injections of alcohol and exposure to stress. Neuropsychopharmacology 21: 435-444.
86. Liechti ME, Lhuillier L, Kaupmann K, Markou A, (2007) Metabotropic glutamate 2/3 receptors in the ventral tegmental area and the nucleus accumbens shell are involved in behaviors relating to nicotine dependence. J Neurosci 27: 9077-9085.
87. Lin N, Hubbard JI, (1994) The increased ethanol preference in rats induced by choice, darkness, or drugs is reduced by ritanserin. Brain Res Bull 33: 633-638.
88. Liu X, Weiss F, (2002a) Additive effect of stress and drug cues on reinstatement of ethanol seeking: exacerbation by history of dependence and role of concurrent activation of corticotropin-releasing factor and opioid mechanisms. J Neurosci 22: 7856-7861.
89. Liu X, Weiss F, (2002b) Reversal of ethanol-seeking behavior by D1 and D2 antagonists in an animal model of relapse: differences in antagonist potency in previously ethanol-dependent versus nondependent rats. J Pharmacol Exp Ther 300: 882-889.
90. Lyon JE, Khan RA, Gessert CE, Larson PM, Renier CM, (2011) Treating alcohol withdrawal with oral baclofen: a randomized, double-blind, placebo-controlled trial. J Hosp Med 6: 469-474.
91. Majchrowicz E, (1975) Induction of physical dependence upon ethanol and the associated behavioral changes in rats. Psychopharmacologia 43: 245-254.
92. Makino S, Schulkin J, Smith MA, Pacák K, Palkovits M, Gold PW, (1995) Regulation of corticotropin-releasing hormone receptor messenger ribonucleic acid in the rat brain and pituitary by glucocorticoids and stress. Endocrinology 136: 4517-4525.
93. Marinelli PW, Funk D, Juzytsch W, Harding S, Rice KC, Shaham Y, Lê AD, (2007) The CRF1 receptor antagonist antalarmin attenuates yohimbine-induced increases in operant alcohol self-administration and reinstatement of alcohol seeking in rats. Psychopharmacology (Berl) 195: 345-355.
94. Markou A, Kosten TR, Koob GF, (1998) Neurobiological similarities in depression and drug dependence: a self-medication hypothesis. Neuropsychopharmacology 18: 135-174.
95. Martin-Fardon R, Zorrilla EP, Ciccocioppo R, Weiss F, (2010) Role of innate and drug-induced dysregulation of brain stress and arousal systems in addiction: focus on corticotropin-releasing factor, nociceptin/orphanin FQ, and orexin/hypocretin. Brain Res 1314: 145-161.
96. Mayo-Smith MF, (1997) Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA 278: 144-151.
97. McBride WJ, Le A-D, Noronha A, (2002) Central nervous system mechanisms in alcohol relapse. Alcohol Clin Exp Res 26: 280-286.
98. Meert TF, Awouters F, Niemegeers CJ, Schellekens KH, Janssen PA, (1991) Ritanserin reduces abuse of alcohol, cocaine, and fentanyl in rats. Pharmacopsychiatry 24: 159-163.
99. Meinhardt MW, (2013) The glutamate system in alcohol dependence-implications from the postdependent phenotype. PhD thesis.
100. Meinhardt MW, Hansson AC, Perreau-Lenz S, Bauder-Wenz C, Stählin O, Heilig M, Harper C, Drescher KU, Spanagel R, Sommer WH, (2013) Rescue of infralimbic mGluR2 deficit restores control over drug-seeking behavior in alcohol dependence. J Neurosci 33: 2794-2806.
101. Melendez RI, McGinty JF, Kalivas PW, Becker HC, (2012) Brain region-specific gene expression changes after chronic intermittent ethanol exposure and early withdrawal in C57BL/6J mice. Addict Biol 17: 351-364.
102. Molander A, Vengeliene V, Heilig M, Wurst W, Deussing JM, Spanagel R, (2012) Brain-specific inactivation of the Crhr1 gene inhibits post-dependent and stress-induced alcohol intake, but does not affect relapse-like drinking. Neuropsychopharmacology 37: 1047-1056.
103. Murtra P, Sheasby AM, Hunt SP, De Felipe C, (2000) Rewarding effects of opiates are absent in mice lacking the receptor for substance P. Nature 405: 180-183.
104. Naranjo CA, Knoke DM, (2001) The role of selective serotonin reuptake inhibitors in reducing alcohol consumption. J Clin Psychiatry 62 (Suppl. 2): 18-25.
105. Nelson EC, Agrawal A, Pergadia ML, Wang JC, Whitfield JB, Saccone FS, Kern J, Grant JD, Schrage AJ, Rice JP, Montgomery GW, Heath AC, Goate AM, Martin NG, Madden PAF, (2010) H2 haplotype at chromosome 17q21.31 protects against childhood sexual abuse-associated risk for alcohol consumption and dependence. Addict Biol 15: 1-11.
106. Ng GY, George SR, (1994) Dopamine receptor agonist reduces ethanol self-administration in the ethanol-preferring C57BL/6J inbred mouse. Eur J Pharmacol 269: 365-374.
107. Ng GY, O'Dowd BF, George SR, (1994) Genotypic differences in brain dopamine receptor function in the DBA/2J and C57BL/6J inbred mouse strains. Eur J Pharmacol 269: 349-364.
108. Noori HR, Helinski S, Spanagel R, (2014) Cluster and meta-analyses on factors influencing stress-induced alcohol drinking and relapse in rodents. Addict Biol 19: 225-232.
109. Nunes EV, Levin FR, (2004) Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA 291: 1887-1896.
110. O'Brien ES, Legastelois R, Houchi H, Vilpoux C, Alaux-Cantin S, Pierrefiche O, André E, Naassila M, (2011) Fluoxetine, desipramine, and the dual antidepressant milnacipran reduce alcohol self-administration and/or relapse in dependent rats. Neuropsychopharmacology 36: 1518-1530.
111. O'Dell LE, Roberts AJ, Smith RT, Koob GF, (2004) Enhanced alcohol self-administration after intermittent versus continuous alcohol vapor exposure. Alcohol Clin Exp Res 28: 1676-1682.
112. Pacher P, Kunos G, (2013) Modulating the endocannabinoid system in human health and disease-successes and failures. FEBS J 280: 1918-1943.
113. Panocka I, Massi M, (1992) Long-lasting suppression of alcohol preference in rats following serotonin receptor blockade by ritanserin. Brain Res Bull 28: 493-496.
114. Ramchandani VA, Umhau J, Pavon FJ, Ruiz-Velasco V, Margas W, Sun H, Damadzic R, Eskay R, Schoor M, Thorsell A, Schwandt ML, Sommer WH, George DT, Parsons LH, Herscovitch P, Hommer D, Heilig M, (2011) A genetic determinant of the striatal dopamine response to alcohol in men. Mol Psychiatry 16: 809-817.
115. Refojo D, Schweizer M, Kuehne C, Ehrenberg S, Thoeringer C, Vogl AM, Dedic N, Schumacher M, von Wolff G, Avrabos C, Touma C, Engblom D, Schütz G, Nave KA, Eder M, Wotjak CT, Sillaber I, Holsboer F, Wurst W, Deussing JM, (2011) Glutamatergic and dopaminergic neurons mediate anxiogenic and anxiolytic effects of CRHR1. Science 333: 1903-1907.
116. Rhodes JS, Best K, Belknap JK, Finn DA, Crabbe JC, (2005) Evaluation of a simple model of ethanol drinking to intoxication in C57BL/6J mice. Physiol Behav 84: 53-63.
117. Rigotti NA, Gonzales D, Dale LC, Lawrence D, Chang Y, (2009) A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain. Addiction 104: 266-276.
118. Rimondini R, Arlinde C, Sommer W, Heilig M, (2002) Long-lasting increase in voluntary ethanol consumption and transcriptional regulation in the rat brain after intermittent exposure to alcohol. FASEB J 16: 27-35.
119. Rimondini R, Sommer W, Heilig M, (2003) A temporal threshold for induction of persistent alcohol preference: behavioral evidence in a rat model of intermittent intoxication. J Stud Alcohol 64: 445-449.
120. Rimondini R, Thorsell A, Heilig M, (2005) Suppression of ethanol self-administration by the neuropeptide Y (NPY) Y2 receptor antagonist BIIE0246: evidence for sensitization in rats with a history of dependence. Neurosci Lett 375: 129-133.
121. Rimondini R, Sommer WH, Dall'Olio R, Heilig M, (2008) Long-lasting tolerance to alcohol following a history of dependence. Addict Biol 13: 26-30.
122. Roberts AJ, Heyser CJ, Cole M, Griffin P, Koob GF, (2000) Excessive ethanol drinking following a history of dependence animal model of allostasis. Neuropsychopharmacology 22: 581-594.
123. Rodd ZA, McKinzie DL, Bell RL, McQueen VK, Murphy JM, Schoepp DD, McBride WJ, (2006) The metabotropic glutamate 2/3 receptor agonist LY404039 reduces alcohol-seeking but not alcohol self-administration in alcohol-preferring (P) rats. Behav Brain Res 171: 207-215.
124. Rodríguez de Fonseca F, Roberts AJ, Bilbao A, Koob GF, Navarro M, (1999) Cannabinoid receptor antagonist SR141716A decreases operant ethanol self administration in rats exposed to ethanol-vapor chambers. Zhongguo Yao Li Xue Bao 20: 1109-1114.
125. Rogers J, Wiener SG, Bloom FE, (1979) Long-term ethanol administration methods for rats: advantages of inhalation over intubation or liquid diets. Behav Neural Biol 27: 466-486.
126. Saavedra JM, Benicky J, (2007) Brain and peripheral angiotensin II play a major role in stress. Stress 10: 185-193.
127. Sanchis-Segura C, Spanagel R, (2006) Behavioural assessment of drug reinforcement and addictive features in rodents: an overview. Addict Biol 11: 2-38.
128. Sarviharju M, Riikonen J, Jaatinen P, Sinclair D, Hervonen A, Kiianmaa K, (2004) Survival of AA and ANA rats during lifelong ethanol exposure. Alcohol Clin Exp Res 28: 93-97.
129. Schank JR, Pickens CL, Rowe KE, Cheng K, Thorsell A, Rice KC, Shaham Y, Heilig M, (2011) Stress-induced reinstatement of alcohol-seeking in rats is selectively suppressed by the neurokinin 1 (NK1) antagonist L822429. Psychopharmacology (Berl) 218: 111-119.
130. Schank JR, Tapocik JD, Barbier E, Damadzic R, Eskay RL, Sun H, Rowe KE, King CE, Yao M, Flanigan ME, Solomon MG, Karlsson C, Cheng K, Rice KC, Heilig M, (2013) Tacr1 gene variation and neurokinin 1 receptor expression is associated with antagonist efficacy in genetically selected alcohol-preferring rats. Biol Psychiatry 73: 774-781.
131. Schulkin J, Gold PW, McEwen BS, (1998) Induction of corticotropin-releasing hormone gene expression by glucocorticoids: implication for understanding the states of fear and anxiety and allostatic load. Psychoneuroendocrinology 23: 219-243.
132. Semenova S, Markou A, (2007) The effects of the mGluR5 antagonist MPEP and the mGluR2/3 antagonist LY341495 on rats' performance in the 5-choice serial reaction time task. Neuropharmacology 52: 863-872.
133. Shen Y, Lindemeyer AK, Gonzalez C, Shao XM, Spigelman I, Olsen RW, Liang J, (2012) Dihydromyricetin as a novel anti-alcohol intoxication medication. J Neurosci 32: 390-401.
134. Sidhpura N, Weiss F, Martin-Fardon R, (2010) Effects of the mGlu2/3 agonist LY379268 and the mGlu5 antagonist MTEP on ethanol seeking and reinforcement are differentially altered in rats with a history of ethanol dependence. Biol Psychiatry 67: 804-811.
135. Simpson TL, Saxon AJ, Meredith CW, Malte CA, McBride B, Ferguson LC, Gross CA, Hart KL, Raskind M, (2009) A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence. Alcohol Clin Exp Res 33: 255-263.
136. Sinclair JD, Li TK, (1989) Long and short alcohol deprivation: effects on AA and P alcohol-preferring rats. Alcohol 6: 505-509.
137. Sommer W, Arlinde C, Heilig M, (2005a) The search for candidate genes of alcoholism: evidence from expression profiling studies. Addict Biol 10: 71-79.
138. Sommer W, Hyytiä P, Kiianmaa K, (2006) The alcohol-preferring AA and alcohol-avoiding ANA rats: neurobiology of the regulation of alcohol drinking. Addict Biol 11: 289-309.
139. Sommer WH, Saavedra JM, (2008) Targeting brain angiotensin and corticotrophin-releasing hormone systems interaction for the treatment of mood and alcohol use disorders. J Mol Med (Berl) 86: 723-728.
140. Sommer WH, Rimondini R, Heilig M, Hyytiä P, Ciccocioppo R, (2005b) Expression of brain Na,K-ATPase in animal models of alcoholism. Alcohol Alcohol Suppl 40: il-63.
141. Sommer WH, Rimondini R, Marquitz M, Lidström J, Siems W-E, Bader M, Heilig M, (2007) Plasticity and impact of the central renin-angiotensin system during development of ethanol dependence. J Mol Med (Berl) 85: 1089-1097.
142. Sommer WH, Rimondini R, Hansson AC, Hipskind PA, Gehlert DR, Barr CS, Heilig MA, (2008) Upregulation of voluntary alcohol intake, behavioral sensitivity to stress, and amygdala Crhr1 expression following a history of dependence. Biol Psychiatry 63: 139-145.
143. Sommer WH, Mann K, Hyytiä P, Canals S, Meinhardt MW, Vollstädt-Klein S, Hermann D, Weber-Fahr W, (2013) Translational neuroimaging in alcoholism (TRANSALC): identification of altered brain connectivity and treatment efficacy predictors. SFN Poster.
144. Soyka M, Koller G, Schmidt P, Lesch O-M, Leweke M, Fehr C, Gann H, Mann KF, (2008) Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial. J Clin Psychopharmacol 28: 317-324.
145. Spanagel R, (2009) Alcoholism: a systems approach from molecular physiology to addictive behavior. Physiol Rev 89: 649-705.
146. Spanagel R, Weiss F, (1999) The dopamine hypothesis of reward: past and current status. Trends Neurosci 22: 521-527.
147. Spanagel R, Zieglgänsberger W, (1997) Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes. Trends Pharmacol Sci 18: 54-59.
148. Spanagel R, Hölter SM, Allingham K, Landgraf R, Zieglgänsberger W, (1996) Acamprosate and alcohol: I. Effects on alcohol intake following alcohol deprivation in the rat. Eur J Pharmacol 305: 39-44.
149. Steensland P, Simms JA, Holgate J, Richards JK, Bartlett SE, (2007) Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc Natl Acad Sci U S A 104: 12518-12523.
150. Szczepanska-Sadowska E, Cudnoch-Jedrzejewska A, Ufnal M, Zera T, (2010) Brain and cardiovascular diseases: common neurogenic background of cardiovascular, metabolic and inflammatory diseases. J Physiol Pharmacol 61: 509-521.
151. Tapocik JD, Solomon M, Flanigan M, Meinhardt M, Barbier E, Schank JR, Schwandt M, Sommer WH, Heilig M, (2013) Coordinated dysregulation of mRNAs and microRNAs in the rat medial prefrontal cortex following a history of alcohol dependence. Pharmacogenomics J 13: 286-296.
152. Torricelli P, Fini M, Giavaresi G, Borsari V, Rimondini L, Rimondini R, Carrassi A, Giardino R, (2007) Intermittent exposure to ethanol vapor affects osteoblast behaviour more severely than estrogen deficiency does in vitro study on rat osteoblasts. Toxicology 237: 168-176.
153. Treutlein J, Kissling C, Frank J, Wiemann S, Dong L, Depner M, Saam C, Lascorz J, Soyka M, Preuss UW, Rujescu D, Skowronek MH, Rietschel M, Spanagel R, Heinz A, Laucht M, Mann K, Schumann G, (2006) Genetic association of the human corticotropin releasing hormone receptor 1 (CRHR1) with binge drinking and alcohol intake patterns in two independent samples. Mol Psychiatry 11: 594-602.
154. Trzaskowska E, Kostowski W, (1983) Further studies on the role of noradrenergic mechanisms in ethanol withdrawal syndrome in rats. Pol J Pharmacol Pharm 35: 351-358.
155. Ubaldi M, Bifone A, Ciccocioppo R, (2013) Translational approach to develop novel medications on alcohol addiction: focus on neuropeptides. Curr Opin Neurobiol 23: 684-691.
156. Umhau JC, Momenan R, Schwandt ML, Singley E, Lifshitz M, Doty L, Adams LJ, Vengeliene V, Spanagel R, Zhang Y, Shen J, George DT, Hommer D, Heilig M, (2010) Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study. Arch Gen Psychiatry 67: 1069-1077.
157. Valdez GR, Zorrilla EP, Roberts AJ, Koob GF, (2003) Antagonism of corticotropin-releasing factor attenuates the enhanced responsiveness to stress observed during protracted ethanol abstinence. Alcohol 29: 55-60.
158. Vendruscolo LF, Barbier E, Schlosburg JE, Misra KK, Whitfield TW, Logrip ML, Rivier C, Repunte-Canonigo V, Zorrilla EP, Sanna PP, Heilig M, Koob GF, (2012) Corticosteroid-dependent plasticity mediates compulsive alcohol drinking in rats. J Neurosci 32: 7563-7571.
159. Vengeliene V, Heidbreder CA, Spanagel R, (2007) The effects of lamotrigine on alcohol seeking and relapse. Neuropharmacology 53: 951-957.
160. Walker BM, Koob GF, (2007) The gamma-aminobutyric acid-B receptor agonist baclofen attenuates responding for ethanol in ethanol-dependent rats. Alcohol Clin Exp Res 31: 11-18.
161. Walker BM, Koob GF, (2008) Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence. Neuropsychopharmacology 33: 643-652.
162. Walker BM, Rasmussen DD, Raskind MA, Koob GF, (2008) Alpha1-noradrenergic receptor antagonism blocks dependence-induced increases in responding for ethanol. Alcohol 42: 91-97.
163. Walker BM, Zorrilla EP, Koob GF, (2011) Systemic κ-opioid receptor antagonism by nor-binaltorphimine reduces dependence-induced excessive alcohol self-administration in rats. Addict Biol 16: 116-119.
164. Wise RA, (1975) Maximization of ethanol intake in the rat. Adv Exp Med Biol 59: 279-294.
165. Wolffgramm J, Galli G, Thimm F, Heyne A, (2000) Animal models of addiction: models for therapeutic strategies? J Neural Transm 107: 649-668.
166. Zhao Y, Dayas CV, Aujla H, Baptista MA, Martin-Fardon R, Weiss F, (2006) Activation of group II metabotropic glutamate receptors attenuates both stress and cue-induced ethanol-seeking and modulates c-fos expression in the hippocampus and amygdala. J Neurosci 26: 9967-9974.
167. Zhou Z, Karlsson C, Liang T, Xiong W, Kimura M, Tapocik JD, Yuan Q, Barbier E, Feng A, Flanigan M, Augier E, Enoch M-A, Hodgkinson CA, Shen P-H, Lovinger DM, Edenberg HJ, Heilig M, Goldman D, (2013) Loss of metabotropic glutamate receptor 2 escalates alcohol consumption. Proc Natl Acad Sci U S A 110: 16963-16968.
168. Zorrilla EP, Heilig M, de Wit H, Shaham Y, (2013) Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism. Drug Alcohol Depend 128: 175-186.